![Sad tired sick asthmatic teenager with scarf around neck temperature check using thermometer](http://images.ctfassets.net/lbag5qm9ugnj/nuDonN06nmWtlnEdQxb70/1f1bb1964c96fcf7e7d7af7511bfb917/iStock-1422285406.jpg)
Author’s note: ‘Jared’ is an actual patient; however, the details of his history have been altered to preserve his privacy. Nevertheless, Jared’s successful asthma management is a true story repeated several times in my practice.
Key Takeaways
Montelukast helps with asthma control
Six months of Montelukast use results in a reduction in nighttime awakenings and daytime symptoms
Montelukast improves lung function, with FEV1 increasing from 75% to 85% in Jared’s case
Montelukast blocks leukotrienes, reducing inflammation and bronchoconstriction
Personalized asthma management and regular follow-ups are essential to improve patients’ quality of life.
Jared is a 15-year-old boy with a history of moderate persistent asthma, which I diagnosed when he was ten years old. Jared reported frequent asthma symptoms, including wheezing, shortness of breath, chest tightness, and coughing, especially at night and early morning.
Jared had a history of seasonal allergies, which is typical for many patients with asthma. His mother told me that when she has a cold, it ‘goes into her chest,’ which is a clue that she probably has a form of asthma (although I did not check her; Jared’s mother is not my patient!)
As I do with all my patients with asthma, I performed spirometry in my office and found that Jared had significant reversible small airway narrowing, a cardinal signal of asthma. Jared used a rescue inhaler (albuterol) when he had symptoms and before gym class.
I initially managed Jared with a daily inhaled corticosteroid (budesonide) at 400 mcg/day according to guidelines. Despite his adherence to this regimen, Jared continued to experience frequent symptoms and worsening, suggesting poor asthma control. For example, every time Jared had a cold, he would have a severe asthma attack; he also told me that he could not play soccer without wheezing despite taking albuterol half an hour before a game.
Addition of Montelukast to Jared’s Regimen
I decided to add montelukast, a leukotriene receptor antagonist, at a dose of 10 mg once daily to better control inflammatory processes and reduce the frequency and severity of asthma symptoms. I monitored Jared with spirometry over six months after adding montelukast.
Jared’s symptoms significantly improved. The frequency of nighttime awakenings due to asthma was reduced to once per week. Daytime symptoms were minimal and infrequent. There was a notable reduction in the number of asthma exacerbations, and he never had to visit the emergency room.
Spirometry indicated improved lung function, with his FEV1 (Forced Expiratory Volume in one second) increasing from 75% to 85% of the predicted value. Jared reported an overall improvement in the quality of life, with better participation in soccer and fewer absences from school.
Why Monteleukast?
Asthma management typically follows a stepwise approach. For patients like Jared, who have moderate persistent asthma, inhaled corticosteroids serve as the first-line treatment. However, in some cases, additional medications may be necessary to attain optimal control. Montelukast is an effective add-on therapy in such cases. In Jared’s case, the addition of montelukast led to significant clinical improvement, indicating its efficacy in managing symptoms not fully controlled by budesonide alone.
Montelukast, a leukotriene receptor antagonist, plays a crucial role in asthma management, particularly as adjunct therapy for patients with moderate persistent asthma who do not achieve adequate control with inhaled corticosteroids alone. Leukotrienes are inflammatory mediators produced by the metabolism of arachidonic acid in the body, primarily by mast cells and eosinophils. They contribute to various aspects of asthma pathology, including bronchoconstriction, mucus production, vascular permeability, and eosinophil recruitment.
Montelukast works by selectively binding to cysteinyl leukotriene receptors on airway smooth muscle cells and other target tissues, blocking the action of leukotrienes. This antagonism helps prevent leukotriene-induced bronchoconstriction, inflammation, and other respiratory symptoms associated with asthma. By inhibiting these pathways, montelukast reduces the frequency and severity of asthma symptoms, decreases nocturnal symptoms, and improves overall lung function.
As adjunct therapy, montelukast primarily benefits patients with moderate persistent asthma, who typically experience daily symptoms and may have frequent exacerbations despite regular use of inhaled steroids. Adding montelukast to their treatment regimen can significantly enhance asthma control by targeting different inflammatory pathways that inhaled steroids alone may not fully address.
The usual dosage of montelukast for adolescents aged 15 and older is 10 mg, taken once daily, typically in the evening. This timing helps address nighttime symptoms and improve morning lung function. Clinical trials and real-world studies have demonstrated that combining montelukast with inhaled steroids can reduce asthma exacerbations, improve quality of life, and decrease the need for short-acting beta-agonists, providing a more comprehensive approach to asthma management.
Victory Over Moderate Persistent Asthma
Jared’s case highlights the importance of individualized asthma management plans. For patients with moderate persistent asthma not adequately controlled with daily inhaled steroids, the addition of montelukast can significantly improve symptom control and quality of life. Regular follow-up and reassessment are crucial to ensure optimal management and adjustment of therapy as needed.
Is it Asthma?
Seeking medical attention for asthma is crucial for several reasons. Timely medical intervention ensures proper diagnosis, management, and treatment of the condition. Early and accurate diagnosis is essential for effective asthma management. A healthcare professional can take an appropriate medical history and conduct pulmonary function tests, such as spirometry, to confirm the diagnosis. Once diagnosed, they can tailor a treatment plan that typically includes medications, lifestyle adjustments, and strategies to avoid triggers.
Adherence to a prescribed asthma regimen is vital for controlling symptoms and preventing exacerbations. However, if current treatments fail to provide adequate relief, it is imperative to seek medical advice. This situation could indicate that the asthma is not well-controlled, necessitating adjustments in medication or exploration of alternative therapies. Uncontrolled asthma increases the risk of severe attacks, which can be life-threatening and require emergency care.
Regular follow-ups with a healthcare provider allow for monitoring the condition, ensuring that the treatment remains effective. Asthma management is dynamic, often requiring modifications based on symptoms, environment, or overall health changes. Therefore, seeking medical attention ensures that asthma is managed effectively, improving quality of life and reducing the risk of severe complications.
Rely on PlanetDrugsDirect.com to Buy Prescription Discount Montelukast
As a trusted prescription referral service, we offer important benefits whenever you order online. Each of our partner pharmacies and/or government-approved dispensaries is committed to providing the best experience possible of any online prescription referral service on the internet. We offer:
Low prices
Quick turn-around times
Generic and brand-name medications
Unparalleled customer service
Sources
Chung KF. Montelukast: pharmacokinetics and pharmacodynamics in asthma treatment. Clin Pharmacokinet. 2001;40(5):355-371. doi:10.2165/00003088-200140050-00004
Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-178. doi:10.1183/09031936.00138707
Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol. 2010;125(2 Suppl 2)
National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full Report 2007. NIH publication No. 07-4051. https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf
Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-3556. doi:10.1172/JCI36130
Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-2052. doi:10.1056/NEJMoa063861
Wermuth HR, Badri T, Takov V. Montelukast. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. Accessed June 9, 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482456/